Valuation: Viatris Inc.

Market Cap 20.55B 17.8B 16.59B 15.26B 28.81B 1,954B 29.14B 195B 76.54B 978B 77.2B 75.5B 3,239B P/E 2026 *
77.7x
P/E 2027 * 32.9x
Enterprise Value 32.74B 28.36B 26.44B 24.31B 45.9B 3,113B 46.41B 311B 122B 1,558B 123B 120B 5,159B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 2.11x
Free-Float
92.23%
Yield 2026 *
2.88%
Yield 2027 * 2.96%
1 day-2.75%
1 week-3.05%
1 month+5.33%
3 months+14.08%
6 months+25.66%
Current year+43.23%
1 week 15.15
Extreme 15.146
15.64
1 month 14.17
Extreme 14.172
15.64
Current year 10.52
Extreme 10.52
15.64
1 year 7.65
Extreme 7.648
15.64
3 years 6.45
Extreme 6.452
15.64
5 years 6.45
Extreme 6.452
15.64
10 years 6.45
Extreme 6.452
15.64
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%-3.05% - - 20.55B
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
+0.22%+3.76%+47.51%+38.46% 361B
+0.76%-0.95%+35.95%+39.77% 293B
+0.24%-5.24%+9.04%+10.73% 251B
+4.57%+5.21%+35.91%+67.64% 220B
+1.71%-9.69%+3.23%-45.24% 201B
-2.58%-0.73%+17.16%+67.46% 164B
Average +0.48%-3.81%+30.71%+50.90% 398.79B
Weighted average by Cap. +0.82%-3.79%+38.54%+76.28%

Financials

2026 *2027 *
Net sales 14.78B 12.8B 11.93B 10.98B 20.72B 1,405B 20.95B 140B 55.04B 703B 55.51B 54.29B 2,329B 15.04B 13.03B 12.14B 11.17B 21.08B 1,430B 21.32B 143B 56B 716B 56.49B 55.24B 2,370B
Net income 3.05M 2.64M 2.46M 2.27M 4.28M 290M 4.33M 28.95M 11.36M 145M 11.46M 11.21M 481M 339M 293M 273M 252M 475M 32.21B 480M 3.21B 1.26B 16.12B 1.27B 1.24B 53.38B
Net Debt 12.19B 10.56B 9.84B 9.05B 17.09B 1,159B 17.28B 116B 45.39B 580B 45.78B 44.77B 1,921B 11.2B 9.7B 9.04B 8.31B 15.69B 1,065B 15.87B 106B 41.69B 533B 42.05B 41.12B 1,764B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change Volume
31/07/26 15.22 -0.18% 4
05/08/26 €15.23 -0.01% 25
04/08/26 €15.23 +0.22% 0
03/08/26 €15.19 -0.16% 240
31/07/26 €15.22 -0.18% 4
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
17.65USD
Average target price
17.94USD
Spread / Average Target
+1.63%

Quarterly revenue - Rate of surprise